Literature DB >> 3485102

Effect of interleukin-2 on the manifestation and growth of acetoxymethyl-methylnitrosamine-induced colorectal rat adenocarcinoma.

F T Garzon, M Salas, M R Berger, H Kirchner.   

Abstract

The effect of highly purified human interleukin-2 (IL-2) was assessed on acetoxymethyl-methylnitrosamine(AMMN)-induced colorectal Sprague-Dawley rat adenocarcinoma. Treatment was given for 5 weeks and started 5 weeks after a period of 10 weeks intrarectal administration of 2 mg/kg of AMMN once a week. Animals which showed no evidence of tumors by endoscopical examination of the gut were given 10,000 units/kg of IL-2 s.c. into the dorsal region 5 days a week. Blood samples were analyzed from half of the animals before and 72 h after the end of the treatment. The median tumor volume and the median tumor number per rat were lower in the treated group than in the control. A significant decrease in response to two mitogens (PHA, Con-A) was seen in tumor-bearing rats concomitantly with the tumor growth. The immunological suppression was not restored by treatment with IL-2. No differences in natural killer activity or interferon levels were detected between the control and the treated group. These data indicate some antitumor effect of IL-2 given before the manifestation of tumors in AMMN-induced colorectal rat adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485102     DOI: 10.1007/BF00402782

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  10 in total

Review 1.  Suppressor cells of immune reactivity in malignancy.

Authors:  H Kirchner
Journal:  Eur J Cancer       Date:  1978-05       Impact factor: 9.162

2.  Biologicals and biological response modifiers: fourth modality of cancer treatment.

Authors:  R K Oldham
Journal:  Cancer Treat Rep       Date:  1984-01

3.  Summary: potential of interleukin-2 for the therapy of cancer.

Authors:  R B Herberman
Journal:  J Biol Response Mod       Date:  1984-10

4.  In vivo administration of Interleukin-2 enhances specific alloimmune responses.

Authors:  S A Rosenberg; P J Spiess; S Schwarz
Journal:  Transplantation       Date:  1983-06       Impact factor: 4.939

5.  Colorectal cancer. Prospects in management.

Authors:  W Duncan
Journal:  Recent Results Cancer Res       Date:  1982

6.  Natural killers to rescue immune surveillance?

Authors:  B R Bloom
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

7.  Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer.

Authors:  R K Oldham; G B Thurman; J E Talmadge; H C Stevenson; K A Foon
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

Review 8.  Immunologic approaches to the diagnosis of cancer.

Authors:  R B Herberman
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

9.  Interleukin-2 production in peripheral blood mononuclear cells of patients with gastrointestinal tumors.

Authors:  B Koch; W Regnat; W Solbach; R Lanz; P Hermanek; J R Kalden
Journal:  J Clin Lab Immunol       Date:  1984-04

10.  In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells.

Authors:  S H Hefeneider; P J Conlon; C S Henney; S Gillis
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

  10 in total
  3 in total

1.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Treatment of chemically induced autochthonous rat mammary and colorectal carcinomas with interleukin-2.

Authors:  M R Berger; M Salas; F Garzon; E Petru; U Schwulera; D Schmähl
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Effects of a low-dose IL-2 treatment in HLA-B27 transgenic rat model of spondyloarthritis.

Authors:  L M Araujo; Q Jouhault; I Fert; I Bouiller; G Chiocchia; M Breban
Journal:  Arthritis Res Ther       Date:  2021-07-16       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.